SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results

SELLAS Life Sciences Group (NASDAQ:SLS) posted its quarterly earnings results on Thursday. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05), FiscalAI reports.

SELLAS Life Sciences Group Trading Down 4.6%

SLS stock opened at $8.03 on Friday. The stock has a 50-day moving average price of $11.15 and a two-hundred day moving average price of $8.75. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $15.88. The company has a market cap of $1.62 billion, a PE ratio of -38.24 and a beta of 2.73.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.